The Opportunity
Our Patents
-
- Pondera COPD/Asthma Patent (U.S. Patent No. 8,617,577, December 31, 2013) A method to safely and effectively treat asthma or chronic obstructive pulmonary disease in a subject in need comprising: (a) administering a Receptor Switcher to the subject, wherein the Receptor Switcher is naltrexone in an amount of about 1 microgram to about 500 micrograms; and (b) administering an Endorphin Enhancer, wherein the Endorphin Enhancer is selected from the group consisting of theophylline, roflumilast, ibudilast, cilomilast, zaprinast, rolipram, methylxanthine.
- Pondera Anxiety Disorder patent (U.S. Patent No. 8,741,319, June 3, 2013) A method to safely and effectively treat anxiety conditions, symptoms and/or disorders in a subject in need comprising: (a) administering a Receptor Switcher to the subject, wherein the Receptor Switcher is naltrexone; and (b) administering at least one Endorphin Enhancer to the subject, wherein the Endorphin Enhancer is roflumilast.
- Pondera Endorphinate Patent. (US Patent No. 8,372,414; February 12, 2013) A method to safely and effectively treat Anxiety conditions, symptoms and/or disorders in a subject in need comprising: (a) administering at least one Receptor Switcher to the subject, wherein the receptor switcher is N-acetyl cysteine; and (b) administering at least one Endorphin Enhancer to the subject, wherein the endorphin enhancer is a compound comprising caffeine.
- Partnership and licensing Agreements. Pondera will consider entering into appropriate and mutually beneficial partnership and licensing agreements in the United States, Canada, Europe, South America, Asia and Africa for Endorphinate® commercialization.
- Manufacturing. Pondera is seeking manufacturers in the United States, Canada, Europe, South America, Asia and Africa to produce Endorphinate® for these markets.
- Distribution and sales. Pondera is seeking to establish distribution and sales relationship with companies in the United States, Canada, Europe, South America, Asia and Africa to distribute and sell Endorphinate®.
For access to Confidential Financial, Scientific, Research and Strategic Partnership Information, please contact:
William E. Crain, President & CEO
Pondera Pharmaceuticals, Inc.
209 Chadsey Road, Pownal ME 04069
william@ponderapharma.com